# Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

> **NCT05177796** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Breast Inflammatory Carcinoma
- Invasive Breast Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Panitumumab
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05177796
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-11
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 participants recruited
- **Last updated:** 2024-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177796, "Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05177796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*